Regeneron Pharmaceuticals' Operating Expenses rose 733.83% to $3.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.8 billion, marking a year-over-year increase of 542.24%. This contributed to the annual value of $10.8 billion for FY2025, which is 542.24% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Operating Expenses stood at $3.0 billion for Q4 2025, which was up 733.83% from $2.7 billion recorded in Q3 2025.
Regeneron Pharmaceuticals' Operating Expenses' 5-year high stood at $3.0 billion during Q4 2025, with a 5-year trough of $1.4 billion in Q1 2021.
Over the past 5 years, Regeneron Pharmaceuticals' median Operating Expenses value was $2.3 billion (recorded in 2021), while the average stood at $2.2 billion.
In the last 5 years, Regeneron Pharmaceuticals' Operating Expenses surged by 8409.11% in 2021 and then plummeted by 245.63% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Operating Expenses stood at $2.3 billion in 2021, then decreased by 1.92% to $2.3 billion in 2022, then increased by 8.55% to $2.5 billion in 2023, then increased by 13.72% to $2.8 billion in 2024, then grew by 7.34% to $3.0 billion in 2025.
Its Operating Expenses was $3.0 billion in Q4 2025, compared to $2.7 billion in Q3 2025 and $2.6 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value